Group 1 - The company has received FDA approval for the production site transfer of Lefamulin Injection, 150 mg/15 mL, to its subsidiary, Jianjin Pharmaceutical Co., Ltd. [1][2] - Lefamulin Injection, marketed as XENLETA, was originally approved by the FDA in August 2019 and is currently not available as a generic in the U.S. market [1][6] - The company has invested approximately RMB 19.33 million in the research and development of the Lefamulin production site transfer project [2] Group 2 - The approval of this product enhances the company's international product pipeline and strengthens its market presence [3] - If the product progresses to market sales in the U.S., it is expected to have a positive impact on the company's operating performance [3]

Core Viewpoint - The announcement indicates that the company has received FDA approval for the production site transfer of Lamotrigine Injection, allowing its subsidiary to manufacture the product in a new facility [1] Group 1: Company Developments - The company, Jianyou Co., has announced that its subsidiary, Hong Kong Jianyou Industrial Co., has received a production site transfer approval from the U.S. FDA for Lamotrigine Injection, 150mg/15mL [1] - The approval is associated with New Drug Application (NDA) number 211673, which is crucial for the company's operational capabilities in the U.S. market [1] Group 2: Regulatory Milestones - The FDA's approval signifies a regulatory milestone for the company, enhancing its ability to produce and supply Lamotrigine Injection in compliance with U.S. standards [1] - This development may lead to increased production capacity and potential revenue growth for the company as it expands its manufacturing capabilities [1]

Core Viewpoint - The announcement indicates that the application for the transfer of the production site for Lefamulin injection, 150mg/15mL, has been approved by the FDA, which is a significant development for the company and its product line [1] Group 1: Company Developments - The subsidiary Hong Kong Jianyou has successfully submitted a New Drug Application (NDA) to the FDA for Lefamulin injection [1] - The production site for Lefamulin injection has been transferred to Jianjin Pharmaceutical Co., Ltd., and this application has received FDA approval [1] - Lefamulin injection, marketed under the brand name XENLETA, was initially approved by the FDA on August 19, 2019 [1] Group 2: Market Context - Currently, there are no approved generic versions of Lefamulin injection available in the U.S. market [1]